-Results Will be Presented at the American Society for Mass Spectrometry
56th ASMS Conference in Denver, June 2-5, 2008-
EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) today announced that it has developed a novel analytical 2-dimensional liquid chromatography mass spectrometry-based (LC/LC-MS/MS) multiplexing platform that allows for the rapid, specific, sensitive automated quantification of the active pharmaceutical compounds of MF101, the company's most advanced drug candidate. The novel quantification has been initially developed for, MF101, which is botanically derived, and has shown positive Phase 2 results for the treatment of hot flashes associated with menopause. The assay was validated in multiple matrices ranging from MF101 extracts for production quality control to plasma in pharmacokinetic and safety trials.
"The development of botanical drugs is far more challenging than a single molecule drug, since these are complex mixtures containing a number of bioactive compounds," said the lead author, Dr. Yan Ling Zhang, Bionovo's Director, Analytical Chemistry. "Our assay is capable of sensitively and specifically quantifying all active MF101 compounds in one short analytical run, and allows us to prove the exquisite precision and consistency of our manufacturing process. This is a tremendous advantage over conventional assays that usually only measure single compounds."
"The availability of this robust high-throughput assay is a key to the
fast and successful development of MF101," said Dr. Isaac Cohen, Bionovo's
Chairman and Chief Executive Officer. "Having the tool to quantify multiple
actives solves important questions for manufacturing controls, dose
|SOURCE Bionovo Inc.|
Copyright©2008 PR Newswire.
All rights reserved